Latest collaboration between Iktos and SRI International (SRI) will invest in research and development of anti-viral therapies.
Reports suggest the project will use Iktos’ generative modeling technology with SRI’s SynFini™, which is a completely automated end-to-end synthetic chemistry system, helped to design optimized compounds and enhance the identification of drug candidates for the treatment of viruses such as influenza and the Wuhan coronavirus (COVID-19).
California based technology company- Iktos promotes application of artificial intelligence (AI) in novel drug design. The deep generative models of Iktos will help to enhance the drug discovery process by automatically designing virtual novel molecules.
In the wake of the recent announcement, Yann Gaston-Mathé, co-founder and CEO of Iktos commented, “Iktos generative AI technology has proven its value and potential to accelerate drug discovery programs in multiple collaborations with renowned pharmaceutical companies. We are eager to apply it to SRI’s endonuclease program, and hope our collaboration with SRI can make a difference and speed up the identification of promising new therapeutic option for the treatment of COVID-19.”
Nonprofit Scientific Research Institute- SRI on the other hand focuses on discovering drugs in order to block endonuclease enzymes, common for many viruses. Such enzymes are involved in blocking host resistance to infection and also in viral replication.
Latest research determines that blocking the SARS virus endonuclease prevents the infection’s pathogenesis, thus leading to a 100 percent survival rate in preclinical models. Experts therefore suggest the COVID-19 endonuclease is a good therapeutic target.
This combination of advanced molecular design and automated production of target molecules along with high-throughput biology will help in providing a paradigm for extremely rapid drug discovery against high-value pharmaceutical targets.
“We look forward to exploring how the integration of Iktos’ AI-driven generative molecule combined with SynFini supports the rapid and efficient discovery of new drugs to treat emerging infectious diseases,” commented Nathan Collins, Ph.D., Chief Strategy Officer of SRI’s Biosciences Division and Head of the SynFini program.